12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bremelanotide: Phase IIb data

Top-line data from a double-blind, North American Phase IIb trial in 327 evaluable premenopausal women with FSD showed that subcutaneous bremelanotide met the primary endpoint of increasing the mean number of satisfying sexual events from baseline to week 16 vs. placebo (0.8 vs. 0.2 events, p=0.018). Bremelanotide also met the secondary endpoints of improving mean FSFI total score (3.55 vs.1.88 points, p=0.0017)...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >